2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 99.855 | 327.188 | 637.416 | 644.017 | 450.620 | 521.274 | 392.632 | 139.819 | 258.212 | 105.777 |
Total Income - EUR | 99.949 | 327.613 | 638.242 | 647.514 | 460.216 | 525.079 | 402.181 | 218.617 | 260.599 | 109.515 |
Total Expenses - EUR | 99.377 | 324.933 | 632.799 | 640.031 | 449.727 | 522.570 | 400.565 | 217.695 | 260.344 | 128.406 |
Gross Profit/Loss - EUR | 572 | 2.680 | 5.443 | 7.483 | 10.489 | 2.509 | 1.616 | 922 | 255 | -18.892 |
Net Profit/Loss - EUR | 472 | 2.236 | 4.572 | 5.853 | 8.408 | 2.082 | 1.363 | 785 | 218 | -18.892 |
Employees | 4 | 7 | 7 | 5 | 2 | 3 | 2 | 3 | 1 | 0 |
Check the financial reports for the company - Neoplaza Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 10.396 | 12.960 | 8.857 | 2.404 | 11.842 | 20.418 | 10.364 | 7.763 | 35.145 | 22.589 |
Current Assets | 55.697 | 102.339 | 179.935 | 146.384 | 212.403 | 162.620 | 207.025 | 127.581 | 515.392 | 639.559 |
Inventories | 17.140 | 9 | 18.471 | 14.051 | 15.538 | 23.647 | 18.120 | 0 | 0 | 0 |
Receivables | 22.419 | 100.065 | 153.969 | 130.220 | 193.930 | 135.317 | 182.909 | 122.357 | 515.260 | 639.542 |
Cash | 16.138 | 2.264 | 7.495 | 2.114 | 2.935 | 3.656 | 5.996 | 5.224 | 131 | 17 |
Shareholders Funds | 516 | 2.757 | 7.301 | 6.441 | 25.015 | 26.647 | 27.504 | 27.679 | 27.983 | 9.007 |
Social Capital | 45 | 45 | 45 | 44 | 9.713 | 9.525 | 9.344 | 9.137 | 9.166 | 9.138 |
Debts | 65.576 | 112.542 | 181.491 | 142.347 | 208.485 | 158.383 | 191.840 | 108.939 | 522.553 | 653.141 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4791 - 4791" | |||||||||
CAEN Financial Year |
4791
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Neoplaza Srl